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The roles of sphingosine kinases SK1 and SK2 in
ischemia–reperfusion injury have not been fully elucidated
since studies have found beneficial effects of SK1 while
others showed no role in this injury. To help resolve this, we
used SK1 or SK2 knockout mice and confirmed that renal
ischemia–reperfusion injury induced SK1, but not SK2, in
the kidneys. Furthermore, knockout or pharmacological
inhibition of SK1 increased injury after renal ischemia–
reperfusion injury. In contrast, lack of SK2 conferred renal
protection following injury. In addition, we used lentiviral
gene delivery to selectively express enhanced green
fluorescent protein (EGFP) or human SK1 coexpressed with
EGFP (EGFP-huSK1) in the kidney. Mice with kidney-specific
overexpression of EGFP-huSK1 had significantly improved
renal function with lower plasma creatinine, renal necrosis,
apoptosis, and inflammation. Moreover, EGFP-huSK1
overexpression in cultured human proximal tubule (HK-2)
cells protected against peroxide-induced necrosis. Selective
overexpression of EGFP-huSK1 led to increased HSP27 mRNA
and protein expression in vivo and in vitro. Functional
protection as well as induction of HSP27 with EGFP-huSK1
overexpression in vivo was blocked with sphingosine-1-
phosphate-1 receptor1 (S1P1) antagonism. Thus, our findings
suggest that SK1 is renoprotective by S1P1 activation and
perhaps HSP27 induction. Kidney-specific expression of SK1
through lentiviral delivery may be a viable therapeutic option
to attenuate renal ischemia–reperfusion injury.
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Renal ischemia–reperfusion injury (IRI) is a significant cause of
acute kidney injury (AKI), a major clinical problem often
leading to multiorgan dysfunction and systemic inflamma-
tion.1 The development of AKI is associated with increased
morbidity and mortality among patients in the intensive care
setting,2 and AKI requiring renal replacement therapy is an
independent predictor of mortality after cardiac surgery.3
Despite continued research on renal protective agents, there are
no proven therapies to reduce AKI in the perioperative setting.4
Sphingosine kinase (SK) is an important regulator of cellular
signaling pathways and exists in two isoforms.5,6 SK leads to the
formation of sphingosine-1-phosphate (S1P), a lysophospholi-
pid functioning as both an extracellular ligand for specific G-
protein-coupled receptors and an intracellular second messenger
in promoting cell growth and survival and the inhibition of
apoptosis.5,7 Activation of the S1P1 receptor (S1P1) has been
shown to be protective in cardiac8 and renal IRI,9–11 but the
roles of SK1 and SK2 in IRI are controversial and have yet to be
fully elucidated. A recent study suggests that constitutive
expression of SK2 may contribute to reduced injury with no
role for SK1 after renal IRI.12 However, in acute lung injury, SK1
was protective and SK2 led to increased injury. Furthermore, in
cardiac IRI, SK1 activation has a potent cytoprotective role.13
In this study, we determined the specific role of SK enzyme
subtypes in renal IRI. We tested the hypothesis that SK1
activation is renoprotective and that selective renal over-
expression of SK1 would improve renal function and reduce
necrosis, inflammation, and apoptosis after IRI in mice. We
used genetically modified strains of mice lacking SK1 (SK1/)
and SK2 (SK2/) enzyme to study the effects of SK subtypes in
renal IRI. In addition, we used intrarenal gene delivery in mice
with a lentiviral vector that expresses either enhanced green
fluorescent protein (EGFP) or human SK1 coexpressing EGFP
(EGFP-huSK1), as well as cultured human proximal tubule
(HK-2) cells infected with EGFP or EGFP-huSK1 lentivirus.
RESULTS
Differential induction of SK activity and mRNA regulation
after renal IRI
We initially measured baseline renal SK activity in wild-type
(WT), SK1/, and SK2/ sham-operated mice (Figure 1a).
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SK1/ and SK2/ mice are congenically derived on a
C57BL/6 background. Compared with WT mice, SK2/
mice had similar renal SK activity at baseline, whereas
SK1/ mice had a large decrease (approximately threefold)
in baseline renal SK activity. With 30 min of renal ischemia
and 24 h of reperfusion (renal IRI), renal SK activity
markedly increased (B4–5-fold) in WT mice and SK2/
mice compared with sham-operated mice. In contrast,
SK1/ mice subjected to renal IRI had no increase in renal
SK activity compared with SK1/ sham-operated mice.
These results demonstrate that there was a significant and
selective upregulation of SK1 and not SK2 activity in mice
in response to renal IRI.
Similarly, there were increased SK1 mRNA levels in WT
and SK2/ mice after renal IRI compared with sham-
operated mice (Figure 1b, representative of four experi-
ments). However, SK2 mRNA levels in WT and SK1/ mice
were unchanged after renal IRI compared with sham-
operated mice, further confirming selective renal SK1
upregulation in response to renal IRI.
Differential roles of SK1 and SK2 in renal injury after IRI
Baseline plasma creatinine (Cr) values (mice not subjected
to anesthesia and surgery) were similar between WT
(Cr¼ 0.31±0.02 mg/dl, N¼ 3), SK1/ (Cr¼ 0.30±
0.02 mg/dl, N¼ 3), and SK2/ (Cr¼ 0.33±0.02 mg/dl,
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Figure 1 |Renal ischemia–reperfusion injury (IRI) upregulates sphingosine kinase (SK)-1, but not SK2, in the kidney. (a) Relative SK
activity (fold over wild-type (WT) sham) from kidneys of WT, SK1/, and SK2/ mice subjected to sham operation or 30min of left renal
ischemia, followed by 24 h of reperfusion (renal IRI). N¼ 5–6 per group. (b) Representative gel images and densitometric quantification of
relative band intensities normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) of semiquantitative reverse transcriptase-PCR
(RT-PCR; of four experiments) of murine (m)-SK1, mSK2, and GAPDH from the kidneys of WT, SK1/, and SK2/ mice after sham operation
or renal IRI. (c) Plasma creatinine (mg/dl) was measured in WT, SK1/, and SK2/ mice after sham operation, 20min of renal ischemia
(20min IRI), or 30min of renal ischemia (30min IRI), followed by 24 h of reperfusion (N¼ 6–8 per group). (d) Representative
photomicrographs of four experiments (hematoxylin and eosin staining, original magnifications  200 and  400) with WT (top panels),
SK1/ (middle panels), and SK2/ (bottom panels) mice subjected to 20min of renal IRI. (e) Plasma creatinine in mice pretreated with
vehicle or the SK inhibitors SKI-II (50mg/kg subcutaneously (s.c.)) or CAY10621 (2mg/kg intravenously (i.v.)) and subjected to sham
operation, 20min of IRI, or 30min of IRI, followed by 24 h of reperfusion (N¼ 6 per group). For all graphs: **Po0.001 vs. WT sham group;
*Po0.001 vs. respective sham groups; #Po0.001 vs. respective WT or vehicle IRI group; wPo0.05 vs. respective WT or vehicle IRI group;
zPo0.001 vs. respective SK1/ IRI group. Data are presented as mean±s.e.m.
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N¼ 3) mice. Plasma creatinine levels were also similar
(although slightly elevated compared with mice not subjected
to surgery) in sham-operated (anesthesia, laparotomy, right
nephrectomy, and recovery) WT, SK1/, and SK2/ mice
(Figure 1c). Plasma creatinine increased in WT, SK1/, and
SK2/ mice subjected to moderate (20 min) or severe
(30 min) renal IRI compared with sham-operated mice. After
both moderate and severe renal IRI, SK1/ mice had
significantly increased renal injury compared with WT
or SK2/ mice with higher plasma creatinine levels. In
contrast, SK2 deficiency provided renal protection as SK2/
mice had significantly lower plasma creatinine levels
compared with WT and SK1/ mice after moderate or
severe renal IRI. Figure 1d demonstrates histological injury in
mice after 20 min of renal IRI. Compared with sham-
operated mice (data not shown), the kidneys of WT mice
developed mild injury with some tubular vacuolization and
proteinaceous casts (Figure 1d, top panels). SK1/ mice
developed more severe injury with increased tubular dilata-
tion and congestion, vacuolization, and simplification
(Figure 1d, middle panels). SK2/ mice had markedly
reduced injury compared with SK1/ mice (Figure 1d,
bottom panels).
Because of the inherent concerns regarding the use of
genetic knockout mice (for example, alterations in the
expression of unrelated proteins), we treated some WT mice
with a selective but nonspecific SK inhibitor (SKI-II) or an
SK1-specific inhibitor (CAY10621) before induction of renal
IRI. We determined that SKI-II inhibited mouse kidney SK
activity in a dose-dependent manner (inhibition of 25±2%
and 85±3% at 25 and 250 mg/ml, respectively, N¼ 4), and
preliminary experiments (N¼ 3) showed that the dose of
SKI-II used in our study reduced plasma S1P levels in mice by
470%. In addition, vehicle, SKI-II, or CAY10621 adminis-
tration had no detrimental effects on renal function in sham-
operated mice (Figure 1e). Mice subjected to moderate
(20 min) or severe (30 min) renal IRI with SKI-II or
CAY10621 treatment had increased plasma creatinine levels
compared with vehicle-treated mice (Figure 1e), providing
further evidence that blocking the induction of SK1 activity
worsened renal function after IRI.
We also demonstrate that administration of a selective
S1P1 agonist, SEW2871 (20 mg/kg p.o. 3 h before ischemia
and 9 h after reperfusion), protected mice against renal
IRI. The vehicle used to administer SEW2871 (10%
dimethylsulfoxide, 25% Tween-20) had no effects on renal
function in sham-operated mice (Cr¼ 0.52±0.01 mg/dl,
N¼ 3), but caused an increase in plasma creatinine after
renal IRI compared with mice not treated with vehicle
(Cr¼ 3.38±0.07 mg/dl, N¼ 7 vs. 2.45±0.10 mg/dl, N¼ 8,
Po0.001). However, when mice were treated with SEW2871,
there was a significant decline in plasma creatinine
(Cr¼ 2.34±0.04 mg/dl, N¼ 8, Po0.001 vs. vehicle IRI).
Taken together, our results indicate that SK1 has protective
effects (most likely via S1P1 activation), whereas SK2
contributes to worsening renal injury after renal IRI.
In vivo renal expression of EGFP or EGFP-huSK1 after
intrarenal lentiviral gene delivery in WT mice
We used lentiviral constructs encoding EGFP or EGFP-huSK1
to selectively express these gene products in the kidneys
of WT mice. Intrarenal lentivirus injection had no adverse
effects in mice. As previously demonstrated,14–16 intrarenal
delivery of lentivirus encoding EGFP or EGFP-huSK1
resulted in robust expression of EGFP in the corticomedul-
lary junction (primarily S3 segments of proximal tubules as
the major tubular segment represented) at 48 h after injection
(Figure 2a, left panels, representative of four experiments)
with minimal EGFP expression (similar to baseline green
autofluorescence) in the contralateral (noninjected) kidney
(data not shown).
To confirm that the cells expressing EGFP-SK1 protein are
proximal tubules, we performed Phaseolus vulgaris leucoag-
glutinin lectin staining in kidney sections. The brush border of
proximal tubules stained heavily with P. vulgaris leucoagglu-
tinin lectin (red, Figure 2a, middle panels), and the merged
images demonstrate that nearly all of the EGFP-expressing cells
are proximal tubules (Figure 2a, right panels). Brush-border
stains were lush, consistent with S3 segment morphology.
We confirmed the expression of EGFP and huSK1 mRNA
in mice renally injected with EGFP and EGFP-huSK1 lentivirus
using reverse transcriptase-PCR. Figure 2b (representative of
four experiments) shows that the kidneys of mice injected with
a lentiviral construct all expressed EGFP mRNA. In contrast,
only EGFP-huSK1-injected mice expressed huSK1 mRNA. We
failed to detect EGFP or huSK1 mRNA in the contralateral
(noninjected) kidneys of lentivirus-injected mice (Figure 2b)
as demonstrated previously.14–16
There were similar SK activity levels in the kidneys of mice
not subjected to lentiviral injection (data not shown),
the contralateral (noninjected) kidneys (Figure 2c), or the
kidneys renally injected with EGFP lentivirus (Figure 2c).
However, when mice were renally injected with EGFP-huSK1
lentivirus, there was a significant increase in renal SK activity,
confirming that the lentiviral construct encoded functional
huSK1 enzyme (Figure 2c).
We measured S1P levels in the injected kidneys (cortex
and corticomedullary junction tissue) and plasma of mice
after lentiviral injection using high-performance liquid
chromatography. Compared with kidneys injected with EGFP
lentivirus, there was a significant increase in renal S1P
levels after renal injection with EGFP-huSK1 lentivirus
(S1P level¼ 2.73±0.32-fold compared with EGFP lenti-
virus-injected samples, N¼ 3, Po0.05). However, plasma
levels of S1P were not different in mice injected with EGFP
lentivirus compared with mice injected with EGFP-huSK1
lentivirus (S1P level¼ 0.95±0.18-fold compared with EGFP
lentivirus-injected samples, N¼ 3).
Renal protection with EGFP-huSK1 expression in mice
Mice renally injected with EGFP or EGFP-huSK1 lentivirus
and subjected to sham operation had normal plasma
creatinine similar to mice without lentiviral injection
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(Figure 3). Mice without lentiviral injection or mice renally
injected with EGFP lentivirus 48 h prior had similar and
significant increases in plasma creatinine after 30 min of renal
ischemia and 24 h of reperfusion compared with sham-
operated mice. In contrast, mice renally injected with
lentivirus encoding EGFP-huSK1 showed significant renal
protection after renal IRI. The protective effects of EGFP-
huSK1 lentivirus were mediated via S1P1 as treatment with
an S1P1-specific antagonist (W146) given before renal IRI
reversed the protection seen in mice renally injected with
EGFP-huSK1 lentivirus (Figure 3).
Mice renally expressing EGFP-huSK1 show less renal
tubular necrosis after renal IRI
Compared with sham-operated mice (Figure 4a, representa-
tive of six experiments), there was significant renal injury
in mice subjected to renal IRI (Figure 4b) and in mice
renally injected with EGFP lentivirus 48 h before renal IRI
(Figure 4c), as evidenced by severe tubular necrosis,
corticomedullary congestion and hemorrhage, and develop-
ment of proteinaceous casts. However, mice renally injected
with lentivirus encoding EGFP-huSK1 had reduced renal
tubular damage and necrosis after renal IRI (Figure 4d)
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Figure 2 |Kidney-specific reconstitution of lentivirus (LV) encoding enhanced green fluorescent protein (EGFP)–human sphingosine
kinase 1 (huSK1) increases renal SK activity. (a) Representative kidney fluorescent photomicrographs of four experiments from mice 48 h
after LV injection (frozen section, original magnification of  40 (top panels) and  600 (bottom panels)) demonstrating predominant
localization of EGFP expression (left panels) in the cortex (C) and corticomedullary junction (CMJ) with relative sparing of the medullary
areas (M). The brush border of proximal tubules was stained using Phaseolus vulgaris leucoagglutinin lectin conjugated to a red fluorescent
dye, demonstrating primarily S3 segments in this region (middle panels), and the merged images demonstrate that the majority of
EGFP-expressing cells are proximal tubules (right panels). (b) Representative gel images of reverse transcriptase-PCR (RT-PCR; of four
experiments) of EGFP, huSK1, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) from the injected and noninjected kidneys of sham
mice renally injected with EGFP or EGFP-huSK1 LV 48 h before sample collection. (c) Relative SK activity (fold over EGFP LV noninjected
kidney) from the injected and noninjected kidneys of mice renally injected with LV encoding EGFP or EGFP-huSK1 (N¼ 6 to 7 per group).
*Po0.01 vs. EGFP LV-injected group. Data are presented as mean±s.e.m.
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compared with mice injected with EGFP lentivirus and mice
not subjected to lentiviral injection.
The Jablonski scale renal injury score histology grading17
was used to grade renal tubular necrosis after renal IRI
(Figure 4e). Mice injected with EGFP or EGFP-huSK1
encoding lentivirus and subjected to sham operation
developed very mild tubular necrosis compared with sham-
operated mice not subjected to lentiviral injection. Renal
ischemia for 30 min and reperfusion for 24 h resulted in
severe acute tubular necrosis in mice subjected to renal IRI
and in mice injected with lentivirus encoding EGFP 48 h
before renal IRI. In contrast, mice renally injected with
lentivirus encoding EGFP-huSK1 48 h before renal IRI had
significantly lower renal injury scores compared with mice
injected with lentivirus encoding EGFP and mice not
subjected to lentiviral injection (Figure 4e).
Mice renally expressing EGFP-huSK1 show reduced
proinflammatory gene expression in the kidney after
renal IRI
There were no differences in the mRNA expressions of tumor
necrosis factor-a, intercellular adhesion molecule-1, mono-
cyte chemoattractive protein-1, macrophage inflammatory
protein-2, and interleukin-6 between sham-operated mice
renally injected with EGFP lentivirus or EGFP-huSK1
lentivirus (Figure 5). We found significantly increased mRNA
expression of these proinflammatory genes in mice subjected
to renal IRI after renal injection with EGFP lentivirus
compared with sham-operated mice. However, mice renally
injected with EGFP-huSK1 lentivirus before renal IRI had
significantly reduced expression of these proinflammatory
mRNAs compared with EGFP lentivirus-injected mice
undergoing renal IRI.
Mice renally expressing EGFP-huSK1 show reduced renal
neutrophil infiltration after renal IRI
Compared with sham-operated mice (Figure 6a, representa-
tive of four experiments), there was an increase in neutrophil
infiltration in mice subjected to renal IRI (Figure 6b) and in
mice renally injected with EGFP lentivirus 48 h before renal
IRI (Figure 6c). In contrast, mice renally injected with
lentivirus encoding EGFP-huSK1 had reduced neutrophil
infiltration after renal IRI (Figure 6d and e).
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Figure 4 |Reduced kidney injury with lentiviral gene delivery
of human sphingosine kinase (huSK)-1 after renal
ischemia–reperfusion injury (IRI). Representative
photomicrographs of six experiments (hematoxylin and eosin
staining, original magnification  200) with mice subjected to
(a) sham operation or (b) renal IRI, or mice renally injected with
(c) enhanced green fluorescent protein (EGFP) or (d) EGFP-huSK1
lentivirus (LV) 48 h before renal IRI. Pictures of the outer medulla
of the kidneys are shown. (e) Jablonski scale renal injury score in
mice without LV injection or mice renally injected with lentivirus
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Mice renally expressing EGFP-huSK1 show reduced renal
apoptosis after renal IRI
We failed to detect significant terminal deoxynucleotidyl
transferase biotin-dUTP nick end labeling (TUNEL)-positive
cells in kidney sections from sham-operated mice (Figure 7a,
representative of four experiments) or in mice subjected to
sham operation after renal injection with EGFP or EGFP-
huSK1 lentivirus (data not shown). Mice subjected to renal
IRI (Figure 7b) or mice renally injected with EGFP lentivirus
before renal IRI (Figure 7c) showed many TUNEL-positive
cells in the corticomedullary junction. However, mice renally
injected with lentivirus encoding EGFP-huSK1 had reduced
TUNEL-positive renal tubule cells (Figure 7d and e).
Selective renal expression of huSK1 upregulates HSP27
in the mouse kidney
Renal expression of EGFP-huSK1 increased renal heat shock
protein 27 (HSP27) mRNA (Figure 8a, representative of four
experiments) and protein (Figure 8b, representative of four
experiments) expressions in mice. As expected, renal IRI led
to an increase in HSP27 expression as EGFP lentivirus-
injected mice subjected to renal IRI had higher HSP27
mRNA (B2-fold) and protein (B10-fold) expression than
EGFP lentivirus-injected mice subjected to sham operation.
Surprisingly, in sham-operated mice, EGFP-huSK1 lentiviral
injection alone led to a sharp increase in HSP27 mRNA
(B6-fold) and protein (B3-fold) compared with mice
injected with EGFP lentivirus. Furthermore, induction of
HSP27 mRNA (B2.4-fold) and protein (B2.2-fold) were
enhanced even further in EGFP-huSK1 lentivirus mice
subjected to renal IRI compared with mice renally injected
with EGFP lentivirus and subjected to renal IRI. Finally,
induction of HSP27 with EGFP-huSK1 lentiviral injection
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Figure 5 | Lentivirus-mediated expression of human
sphingosine kinase (huSK)-1 reduces proinflammatory gene
expression after renal ischemia–reperfusion injury (IRI).
Densitometric quantification of relative band intensities
normalized to glyceraldehyde 3-phosphate dehydrogenase
(GAPDH; fold over enhanced green fluorescent protein (EGFP)
lentivirus (LV) sham group) from semiquantitative reverse
transcriptase-PCR (RT-PCR) reactions for proinflammatory mRNAs
from C57BL/6 mice renally injected with EGFP or EGFP-huSK1 LV
before sham operation or renal IRI (N¼ 5 per group). Intercellular
adhesion molecule-1 (ICAM-1) mRNA expression was not detected
(ND) in sham mice, and hence values are expressed as fold over
the EGFP LV renal IRI group. Abbreviations: IL-6, interleukin-6;
MCP-1, monocyte chemoattractant protein 1; MIP-2, macrophage
inflammatory protein 2; TNF-a, tumor necrosis factor-a. *Po0.001
vs. respective sham group. **Po0.05 vs. respective sham group.
#Po0.001 vs. EGFP LV renal IRI group. wPo0.01 vs. EGFP LV renal
IRI group. zPo0.05 vs. EGFP LV renal IRI group. Data are presented
as mean±s.e.m.
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Figure 6 |Reduced neutrophil infiltration with lentiviral (LV)
gene delivery of human sphingosine kinase (huSK)-1 after
renal ischemia–reperfusion injury (IRI). Representative
photomicrographs of four experiments ( 400) of
immunohistochemistry for neutrophil infiltration in the outer
medulla of the kidneys of mice subjected to (a) sham operation or
(b) renal IRI, or mice renally injected with (c) enhanced green
fluorescent protein (EGFP) or (d) EGFP-huSK1 LV 48 h before renal
IRI. Secondary antibody conjugated to horseradish peroxidase
was developed with diaminobenzidine to stain neutrophils dark
brown. (e) Quantification of neutrophils per high-powered field
(hpf) from the kidneys of mice without LV injection after renal IRI
or mice renally injected with EGFP or EGFP-huSK1 LV before renal
IRI. *Po0.001 vs. no-virus-injected renal IRI group. #Po0.01 vs.
EGFP LV renal IRI group. Data are presented as mean±s.e.m.
1320 Kidney International (2011) 80, 1315–1327
or ig ina l a r t i c l e SW Park et al.: Sphingosine kinase 1 protects in renal ischemia
(Figure 8c, mRNA and protein) was lost when mice were
treated with the S1P1 antagonist W146 before and after
EGFP-huSK1 lentivirus injection.
Overexpression of huSK1 protects HK-2 cells against
H2O2-induced necrosis and upregulates HSP27
Stable overexpression of EGFP-huSK1 in HK-2 cells was
protective against H2O2-induced necrosis compared with
HK-2 cells overexpressing EGFP, confirming our previous
results.18 EGFP HK-2 cells had higher lactate dehydrogenase
(LDH) release (% LDH released¼ 18.1±0.7, N¼ 3) after 3 h
of 2 mmol/l H2O2 treatment compared with EGFP-huSK1
HK-2 cells (% LDH released¼ 12.9±0.8, N¼ 3, Po0.01).
We also found that EGFP-huSK1 HK-2 cells had significantly
increased HSP27 and SK1 mRNA expression (Figure 9a,
representative of four experiments) and protein expression
(Figure 9b, representative of four experiments) compared
with EGFP HK-2 cells.
DISCUSSION
The major findings of this study are as follows: (1) renal IRI
led to significant upregulation of SK1 mRNA expression and
activity in the kidney, whereas SK2 was not affected; (2) this
induction of SK1 was important in mediating protective
effects after renal IRI, as both SK1/ mice and mice treated
with the SK inhibitor SKI-II or the selective SK1 inhibitor
CAY10621 had increased renal injury, whereas SK2/ mice
had a reduction in injury; (3) selective renal overexpression
of huSK1 protected mice against renal IRI in vivo via
activation of S1P1; and (4) SK1 overexpression resulted in
induction of HSP27 mRNA and protein expression in vivo
and in vitro.
AKI remains a significant clinical problem in the
perioperative period, and the development of postoperative
AKI requiring renal replacement therapy carries a 60%
mortality rate.19 AKI is an inflammatory process involving
multiple cellular and systemic responses, including activation
of proinflammatory cytokines and chemokines,20 and
infiltration by leukocytes such as neutrophils, macrophages,
and T cells.21 The inflammatory response is not limited to the
kidney, but affects other organ systems, including the liver,22
intestine,22 lung,23 and heart.24 Multiorgan dysfunction
associated with AKI leads to greatly increased morbidity
and mortality.25 Our studies demonstrate a renal protective
role for SK1, and intrarenal lentiviral delivery of SK1 may be
a therapeutic option to protect against renal IRI.
SK, the enzyme catalyzing the conversion of sphingosine
to S1P, is an important regulator of the putative ‘sphingolipid
rheostat’ that balances the cytoprotective effects of S1P
against the proapoptotic effects of ceramide and sphingo-
sine.7,26 S1P binds to specific G-protein-coupled receptors, of
which five are known (S1P15).
7 The exact roles for the two
subtypes of SK in tissue injury and survival remain
controversial. Of the two known isoforms, SK1 is primarily
known to be cytoprotective, promoting cell survival via the
generation of S1P that signals in an autocrine/paracrine
manner to mediate S1P-receptor-activated signaling.27 The
role of SK2 is not as clear as some studies demonstrate a
proapoptotic and antiproliferative role for SK2,28–30 which
may function independently of S1P receptors,31 whereas
other studies show an antiapoptotic role for SK2, as
inhibiting SK2 or suppressing its expression enhanced
apoptosis in various cancer cells.32 Complicating matters
further, some experimental models demonstrate a proin-
flammatory role of SK1, as SK inhibition33 or mice lacking
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Figure 7 |Reduced apoptosis with lentiviral (LV) gene delivery
of human sphingosine kinase (huSK)-1 after renal
ischemia–reperfusion injury (IRI). Representative fluorescence
photomicrographs (of four experiments) of kidney sections
illustrating apoptotic nuclei (terminal deoxynucleotidyl
transferase biotin-dUTP nick end labeling (TUNEL) fluorescence
staining,  100) in the outer medulla of the kidneys of mice
subjected to (a) sham operation or (b) renal IRI, or mice renally
injected with (c) enhanced green fluorescent protein (EGFP) or
(d) EGFP-huSK1 LV 48h before renal IRI. (e) Quantification of TUNEL-
positive cells per high-powered field (hpf) from the kidneys of
mice without LV injection after renal IRI or mice renally injected
with EGFP or EGFP-huSK1 LV before renal IRI. *Po0.001 vs. no-
virus-injected renal IRI group. #Po0.001 vs. EGFP LV renal IRI
group. Data are presented as mean±s.e.m.
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SK1 enzyme34 had reduced inflammation and colon damage
in a model of Crohn’s disease, and blockade of SK1 reduced
the inflammatory response in endotoxin-mediated sepsis.35
Despite these differences, there is redundancy between
SK1 and SK2 as both SK1/ and SK2/ mice have no
gross phenotypic abnormalities, whereas mice lacking both
SK1 and SK2 are not viable.36,37 The regulation of SK varies
depending on the organ. Cardiac IRI downregulated SK1
activity but did not affect SK2 in the hearts of mice.13 In the
lung, both SK1 and SK2 were upregulated after lipopoly-
saccharide-induced acute lung injury.38
The role that each SK subtype has in renal IRI is not fully
elucidated. We have previously demonstrated that the volatile
anesthetic isoflurane increased plasma membrane transloca-
tion of SK1 to mediate protection against renal IRI in mice.39
In contrast, a recent study by Jo et al.12 suggests that although
SK1 was upregulated after renal IRI, mice lacking SK1 did not
have increased renal dysfunction after renal IRI. On the
contrary, a lack of SK2 resulted in increased renal injury
and neutrophil infiltration after renal IRI.12 We confirm in
this study that only SK1 is upregulated in the kidney after
renal IRI. However, we demonstrate a protective role for
endogenous SK1 and a detrimental role for endogenous SK2
in both models of moderate (20 min) and severe renal
ischemia (30 min). We used a model of contralateral
nephrectomy with unilateral ischemia, whereas Jo et al.12
used a model of bilateral ischemia. The model of AKI used
may result in different outcomes, as it was previously
demonstrated that unilateral or bilateral ischemia resulted
in different effects on subsequent resistance of proximal
tubules to hypoxia.40 Differences in anesthetic agents used
(pentobarbital in our study vs. ketamine, xylazine, and
acepromazine in study by Jo et al.12) may impact the
outcome after renal IRI as several anesthetics (for example,
volatile anesthetics) are known to modulate sphingolipid
metabolism.39,41 It is possible that operative conditions
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Figure 8 | Selective renal expression of human sphingosine kinase (huSK)-1 upregulates heat-shock protein (HSP)-27 expression.
(a) Representative gel images (of four experiments) and densitometric quantification of relative band intensities normalized to
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) of semiquantitative reverse transcriptase-PCR (RT-PCR) of mouse HSP27 and GAPDH
from the renal cortices of C57BL/6 mice renally injected with enhanced green fluorescent protein (EGFP) or EGFP-huSK1 lentivirus (LV) and
subjected to sham operation or renal IRI. (b) Representative immunoblot images (of four experiments) and densitometric quantification of
relative band intensities normalized to b-actin from immunoblot images of mouse HSP27 and b-actin from the renal cortices of C57BL/6
mice renally injected with EGFP or EGFP-huSK1 LV and subjected to sham operation or renal IRI. (c) Representative gel (RT-PCR) and
immunoblot images (of four experiments) of mouse HSP27 and GAPDH (RT-PCR) or HSP27 and b-actin (immunoblot) from the renal cortices
of C57BL/6 mice renally injected with EGFP or EGFP-huSK1 LV and treated with vehicle (veh) or W146 (0.1mg/kg) 15min before and 24 h
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and/or immunomodulatory effects of anesthetics may affect
the outcome of lentiviral overexpression as a therapeutic
modality. In addition, the SK2/ mice that we used and the
SK2tr/tr mice from the Jo et al.12 study were obtained from
different sources37,42 and there may be subtle differences in
local laboratory conditions that may affect outcome. It will be
necessary to reconcile the differences between our models in
future studies. Our findings are consistent with other models
of inflammation as mice lacking SK1 had increased injury
with ischemic preconditioning in cardiac IRI13 and mice
lacking SK1 enzyme had poor recovery from anaphylaxis
with delayed histamine clearance, whereas mice lacking SK2
enzyme had rapid recovery from anaphylaxis.43
Overexpression of SK1 via adenoviral vectors has been
used to demonstrate the protective effects of SK1 in cardiac
IRI44 and acute lung injury.38 We used a lentiviral vector to
selectively and stably express the desired gene products
(EGFP and EGFP-huSK1) in the renal cortex and cortico-
medullary junction of kidneys,14–16 as well as in HK-2 cells.18
There is selective protein expression in injected kidneys when
compared with noninjected kidneys, and mice injected with a
lentiviral construct show robust expression of the targeted
gene products.14–16 The main site of injury in our model of
warm renal IRI is the corticomedullary junction, composed
mainly of S3 segments of the proximal tubule45,46 and HK-2
cells correspond to the cell type in the kidney that is most
susceptible to necrosis after renal IRI.47,48 Using P. vulgaris
leucoagglutinin lectin staining to identify proximal tubule
brush border, we demonstrated that the majority of cells
expressing EGFP were S3 segments of the proximal tubule,
the cells most damaged after ischemic injury. Therefore,
using our method of lentiviral gene delivery, we were able to
directly test the hypothesis that selective expression of huSK1
in the kidney and in HK-2 cells protects against renal IRI
in vivo and H2O2-induced necrosis in vitro.
Selective expression of EGFP-huSK1 protected against
renal IRI as evidenced by a marked reduction in plasma
creatinine levels. The beneficial effects of renal EGFP-huSK1
expression were dependent on S1P1 activation, as mice
treated with an S1P1 antagonist were not protected against
renal IRI after EGFP-huSK1 lentivirus injection. Indeed, our
current and previous studies have implicated the renal
protective role of the S1P1, as S1P or S1P1 agonists such
as FTY720 or SEW2871 were protective in in vivo models of
renal IRI via peripheral lymphopenia9–11 and a reduction in
early renal T-cell infiltration.49 However, a recent study
showed that the protective effects of S1P1 agonism occurred
independently of lymphocytes through direct effects on renal
proximal tubule epithelial cells via activation of the
cytoprotective Akt/ERK pathways.50 Selective expression of
EGFP-huSK1 in the kidneys of mice led to an increase in SK
activity in the kidney, which resulted in a localized increase in
kidney S1P levels, but not in plasma S1P levels. Increased
renal S1P after SK1 lentiviral transduction could have
decreased leukocyte-mediated renal injury in addition to
providing the direct cytoprotective effects on kidney
proximal tubule cells via S1P1 activation after IR. However,
it is possible that, as our targeted gene product was of human
origin, cellular regulation of huSK1 may be different from
regulation of endogenous murine SK1.
The renal protection occurring with EGFP-huSK1 lenti-
viral injection was associated with a decrease in the renal
expression of proinflammatory cytokines, including tumor
necrosis factor-a, intercellular adhesion molecule-1, mono-
cyte chemoattractive protein-1, macrophage inflammatory
protein-2, and interleukin-6. In addition, there was reduced
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Figure 9 |Overexpression of human sphingosine kinase
(huSK)-1 in cultured human proximal tubule (HK-2)
upregulates heat-shock protein (HSP)-27 expression.
(a) Representative gel images (of four experiments) and
densitometric quantification of relative band intensities
normalized to glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) of semiquantitative reverse transcriptase-PCR (RT-PCR)
of HSP27, huSK1, and GAPDH from HK-2 cells infected with
lentivirus encoding enhanced green fluorescent protein (EGFP
HK-2) or EGFP-huSK1 (EGFP-huSK1 HK-2). (b) Representative
immunoblot images (of four experiments) and densitometric
quantification of relative band intensities normalized to b-actin
from immunoblot images of HSP27, SK1, and b-actin from EGFP
HK-2 or EGFP-huSK1 HK-2 cells. *Po0.05 vs. EGFP HK-2 group.
**Po0.01 vs. EGFP HK-2 group. Data are presented as
mean±s.e.m.
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neutrophil infiltration, as well as significantly less renal
tubular necrosis of the ‘outer stripe’ of the outer medulla, and
reduced renal tubular apoptosis. Consistent with the finding
of increased plasma creatinine in SK1/ mice, there were
significant increases in the kidney expression of some
proinflammatory mRNAs in SK1/ mice after renal IRI
compared with WT mice (data not shown). We also
confirmed our previous finding that HK-2 cells overexpres-
sing huSK1 were protected against H2O2-induced necrosis.
18
In our study, selective overexpression of huSK1 strongly
induced HSP27 in the kidney and in HK-2 cells, which was
reversed with S1P1 blockade, suggesting an additional
potential mechanism of cytoprotection with SK1 overexpres-
sion. As we used an overexpression model of huSK1, we must
be cautious in implicating this pathway as the only protective
mechanism in the physiology of the normal mouse. It is
possible that HSP27 may be one of several protective factors
that the SK1-S1P1 pathway regulates to induce renal
protection after IRI. HSPs are a group of molecular
chaperones that are upregulated after various cellular stresses,
including heat shock, hypoxia, ischemia, and toxin expo-
sures.51,52 Increased HSP27 expression protects a cell from
injury or death by functioning as a chaperone to facilitate
proper polypeptide folding, assembly of oligomers, transport,
and conformational changes. We recently demonstrated that
selective renal overexpression of HSP27 in the kidney
protected mice against renal IRI by increasing F-actin
cytoskeletal preservation.15 In addition, translocation
of SK1 to the plasma membrane has been shown to be
coordinated with the actin cytoskeleton in macrophages.53
The induction of HSP27 by SK1 could enhance cytoskeletal
integrity allowing translocation and activation of SK1. S1P
has been shown to induce HSP27 via the p38 mitogen-
activated protein kinase54 and the phosphatidylinositol
3-kinase/Akt55,56 pathways in osteoblasts. Further study will
be necessary to determine the precise relationship between
SK1 and HSP27 in mediating renal protection after IRI.
In conclusion, we show in this study that endogenous
SK1 had protective effects, whereas endogenous SK2
had deleterious effects in a model of murine renal IRI.
In addition, we show that selective renal expression of
the EGFP-huSK1 transgene via lentiviral vector is possible in
the mouse kidney, and that this selective renal overexpression
protects mice against renal IRI via activation of S1P1 and
perhaps via induction of HSP27. These findings may
have important clinical implications, as they imply that
kidney-specific expression of SK1 through lentiviral delivery
is a viable therapeutic option in attenuating the effects
of renal IRI.
MATERIALS AND METHODS
Materials
SKI-II [4-[[4-(4-Chlorophenyl)-2-thiazolyl]amino]phenol] and
SEW2871 (5-[4-Phenyl-5-(trifluoromethyl)-2-thienyl]-3-[3-(tri-
fluoromethyl)phenyl]- 1,2,4-oxadiazole) were purchased from
Tocris Bioscience (Ellisville, MO). CAY10621 [2,2-dimethyl-4S-
(1-oxo-2-hexadecyn-1-yl)-1,1-dimethylethyl ester-3-oxazolidinecar-
boxylic acid] was purchased from Cayman Chemical (Ann Arbor,
MI). W146 [(R)-3-Amino-(3-hexylphenylamino)-4-oxobutylpho-
sphonic acid] was purchased from Avanti Polar Lipids (Alabaster,
AL). Unless otherwise specified, all other reagents were purchased
from Sigma (St Louis, MO).
Intrarenal lentivirus delivery in mice
Lentivirus encoding EGFP-huSK1 was generated by subcloning
huSK1 cDNA into a modified shuttle vector CMV-pLL3.7, in which
the insert expression is driven by a CMV promoter, followed by an
IRES–EGFP sequence for simultaneous coexpression of the EGFP
reporter gene and hemagglutinin (HA) tag. When expressed, this
vector yields two independent proteins, EGFP and the huSK1
protein fused with the HA tag. Lentivirus was produced by a triple
transfection of CMV-huSK1-pLL3.7 or CMV-pLL3.7 (10 mg),
pVSVG (Vesicular stomatitis virus G; Invitrogen, Carlsbad, CA;
7 mg), and pD8.9 (from Dr Van Parjs, MIT, Cambridge, MA; 5 mg) as
previously described.57,58 In vivo virus transduction in mice was
performed as described.14–16
Determination of transgene expression with intrarenal
lentivirus injection
We detected the expression of EGFP and EGFP-huSK1 48 h after
intrarenal injection of lentivirus in mice as described previously.14–16
We also identified proximal tubules by labeling kidney cryosections
using P. vulgaris leucoagglutinin (PHA-L) lectin as described
previously.59 PHA-L lectin binds avidly to the brush border of
proximal tubules.60 Briefly, fixed cryosections were treated with
0.3% H2O2 in methanol for 10 min, 1% bovine serum albumin for
30 min, and then PHA-L conjugated to a fluorescent dye (Alexa
Fluor 594, Invitrogen) for 1 h at room temperature. Overlap of
proximal tubules (red) with EGFP expression (green) was examined
with an Olympus IX81 (Center Valley, PA) epifluorescence
microscope and analyzed with Slidebook software (Intelligent
Imaging Innovations, Denver, CO).
We also extracted total RNA from renal cortices and performed
reverse transcriptase-PCR assays for EGFP, GAPDH (glyceraldehyde
3-phosphate dehydrogenase), and huSK1 as described pre-
viously58,61 (Table 1). In addition, we confirmed the functional
nature of the transgene product by measuring total SK activity as
described previously.39 Briefly, kidney tissues from mice were
collected and homogenized in cell lysate buffer (100 mmol/l sucrose,
1 mmol/l EGTA, 20 mmol/l MOPS, pH 7.4, 5% Percoll, 0.01%
digitonin, protease (Calbiochem, La Jolla, CA), and phosphatase
inhibitors) on ice. After a 1000 g spin for 15 min to pellet cellular
debris, protein concentrations were determined and SK activity
was measured as described by Vessey et al.62 Total SK activity was
also measured in the kidneys of WT, SK1/, and SK2/ mice after
sham operation or renal IRI. To confirm our results, we
supplemented the assay buffer with 0.5% Triton X-100 or 1 mol/l
KCl to create SK1- and SK2-specific assay buffer conditions,
respectively,63 and we found that the rise in SK activity following
renal IRI was entirely due to an increase in SK1 activity and not SK2
activity (data not shown). Our results show that mice with only SK2
enzyme (SK1/ mice) did not have increased SK2 activity after
renal IRI. In contrast, mice with only SK1 enzyme (SK2/ mice)
had significantly increased SK1 activity after renal IRI (5.9±0.7-
fold, N¼ 3, Po0.05 vs. sham). We measured S1P levels in the
kidneys and plasma of mice after lentiviral injection using high-
performance liquid chromatography as described previously.64
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Murine model of renal IRI
All animal protocols were approved by the institutional animal
care and use committee of Columbia University (New York, NY).
We used male C57BL/6 (Harlan, Indianapolis, IN) or SK1/ and
SK2/ mice (kindly provided by RL Proia, NIH, Bethesda,
MD). The generation and initial characterization of SK1/36 and
SK2/37 mice have been described previously. These mice are
congenically derived on a C57BL/6 background. In adult (20–25 g)
male C57BL/6, SK1/, or SK2/ mice, 20- or thirty-min left renal
IRI was performed under pentobarbital anesthesia as described.65
For lentiviral experiments, renal IRI was performed 48 h after
intrarenal injection of EGFP or EGFP-huSK1 lentivirus in C57BL/6
mice as described.14,15 All mice underwent right nephrectomy at the
time of sham operation or renal IRI.
To test the effects of SK inhibition, the SK inhibitors SKI-II or
CAY10621 were administered to mice subjected to renal IRI. SKI-II
(50 mg/kg) was administered subcutaneously 15 min before ische-
mia and 4 h after reperfusion. SKI-II is an SK-selective inhibitor
with minimal effects on other kinases,66 and this dose was shown to
have effective inhibition of activity without significant toxicity.67
CAY10621, an SK1-specific inhibitor with no inhibitory effect on
SK2,68 was administered intravenously (2 mg/kg) 30 min before
ischemia. To test the effects of S1P1 agonism, a selective S1P1
agonist, SEW2871 (20 mg/kg), was administered to mice 3 h before
ischemia and 9 h after reperfusion. SEW2871 was administered via
oral gavage in 10% dimethylsulfoxide/25% Tween-20 as it has low
solubility in aqueous solution.10 To test whether S1P1 antagonism
blocked the renal protective effects of huSK1 overexpression, the
S1P1-specific inhibitor W146 (see ref. 69
69) (0.1 mg/kg) was
administered intraperitoneally 15 min before sham operation or
renal ischemia. To test the effects of S1P1 antagonism on HSP27
mRNA and protein induction after huSK1 overexpression, W146
was administered intraperitoneally 15 min before and 24 h after
lentivirus injection. SKI-II, CAY10621, and W146 were dissolved in
1% dimethylsulfoxide in water (vehicle).
Plasma creatinine level determination
Plasma creatinine levels were measured with an enzymatic creatinine
reagent kit according to the manufacturer’s instructions (Thermo
Fisher Scientific, Waltham, MA).
Histological detection of necrosis
Morphological assessment was performed by an experienced
renal pathologist (VDD) who was unaware of the treatment that
each animal had received. A grading scale of 0–4, as outlined by
Jablonski et al.,17 was used to assess the degree of renal tubular
necrosis in the outer medullary area after renal IRI as described
previously.70,71
Detection of renal tubular apoptosis after renal IRI
We detected apoptosis after renal IRI with TUNEL staining. In situ
labeling of fragmented DNA was performed with TUNEL stain
(green fluorescence) using a commercially available in situ cell-death
detection kit (Roche, Indianapolis, IN) according to the instructions
provided by the manufacturer. TUNEL-positive cells per high-
powered field were counted to quantify apoptosis.
Assessment of renal inflammation
Renal inflammation after IRI was determined (1) with detection of
neutrophil infiltration with immunohistochemistry 24 h after renal
IRI and (2) by measuring mRNA-encoding markers of inflamma-
tion, including interleukin-6, intercellular adhesion molecule-1,
monocyte chemoattractive protein-1, macrophage inflammatory
protein-2, and tumor necrosis factor-a. Immunohistochemistry for
Table 1 | Primers used to amplify mRNAs encoding SK1, SK2, GAPDH, and proinflammatory cytokines based on published
GenBank sequences for mice
Primer Accession number Sequence (sense/antisense)
Product
size (bp)
Cycle
number
Annealing
temp (1C)
Human SK1 NM_021972 50-ATCTCCTTCACGCTGATGC-30
50- GTGCAGAGACAGCAGGTTCA-30
330 26 66
Human HSP27 NM_001540 50-CACGAGGAGCGGCAGGACGAG-30
50-AGTGGCGGCAGCAGGGGTGG-30
286 13 65
Mouse SK1 NM_011451 (variant 1)
NM_025367 (variant 2)
50-GATGCATGAGGTGGTGAATG-30
50-GCCCACTGTGAAACGAATC-30
337 22 64
Mouse SK2 NM_203280 (variant 1)
NM_020011 (variant 2)
50-ACTGCTCGCTTCTTCTCTGC-30
50-ACCATTGAGGGACAGGTCAG-30
437 23 68
Mouse MIP-2 X53798 50-CCAAGGGTTGACTTCAAGAAC-30
50-AGCGAGGCACATCAGGTACG-30
282 28 60
Mouse ICAM-1 X52264 50-TGTTTCCTGCCTCTGAAGC-30
50-CTTCGTTTGTGATCCTCCG-30
409 21 60
Mouse TNF-a X02611 50-TACTGAACTTCGGGGTGATTGGTCC-30
50-CAGCCTTGTCCCTTGAAGAGAACC-30
290 24 65
Mouse MCP-1 NM_011333 50-ACCTGCTGCTACTCATTCAC-30
50-TTGAGGTGGTTGTGGAAAAG-30
312 22 60
Mouse IL-6 NM_031168 50-CCGGAGAGGAGACTTCACAG-30
50-GGAAATTGGGGTAGGAAGGA-30
421 30 62
Mouse HSP27 NM_024441 50-CCTAAGGTCTGGCATGGTA-30
50-AGGAAGCTCGTTGTTGAAGC-30
373 25 66
GAPDH M32599 50-ACCACAGTCCATGCCATCAC-30
50-CACCACCCTGTTGCTGTAGCC-30
450 15 65
Abbreviations: bp, base pairs; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HSP27, heat shock protein 27; ICAM-1, intercellular adhesion molecule-1;
IL-6, interleukin-6; MCP-1, monocyte chemoattractant protein 1; MIP-2, macrophage inflammatory protein 2; SK, sphingosine kinase; TNF-a, tumor necrosis factor-a.
Respective anticipated RT-PCR product size, PCR cycle number for linear amplification, and annealing temperatures used for each primer are also provided.
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neutrophils was performed as described previously70,71 with a
monoclonal antibody against PMN (clone 7/4). A primary antibody
that recognized IgG2a (MCA1212, Serotec, Raleigh, NC) was used as
a negative isotype control in all experiments. Neutrophils per high-
powered field were counted to quantify the degree of neutrophil
infiltration. Semiquantitative reverse transcriptase-PCR assays
for proinflammatory mRNAs, as well as mSK1, mSK2, huSK1,
mHSP27, and huHSP27 mRNA, were performed as described
previously58,61 (Table 1).
Immunoblotting analyses of kidney tissue and HK-2 cells
Mouse kidney cortical tissues (including corticomedullary junc-
tion)72 and HK-2 cell lysates18 were collected for immunoblotting
analyses as described previously. The primary antibody for murine
HSP27 was obtained from Millipore (Billerica, MA). Primary
antibodies for human HSP27 and human SK1 in HK-2 cells were
obtained from Cell Signaling (Danvers, MA). The primary antibody
for b-actin was obtained from Sigma. The secondary antibody
(goat anti-rabbit and anti-mouse IgG conjugated to horseradish
peroxidase in a 1:5000 dilution) was detected with enhanced chemi
luminescence immunoblotting detection reagents (Amersham,
Piscataway, NJ), with subsequent exposure to a CCD camera
coupled to a UVP Bio-imaging System (Upland, CA) and a personal
computer. The band intensities of the immunoblots were within
the linear range of exposure for all experiments.
Cell culture and generation of SK1-overexpressing HK-2 cells
The generation and culture of immortalized human proximal tubule
(HK-2) cells overexpressing wild-type SK1 have been described
previously.18
Induction of HK-2 cell necrosis and measurement of
cell viability with LDH
Necrotic injury in HK-2 cells was induced with exposure to 2 mmol/l
H2O2 for 3 h, and LDH released into cell culture media was measured
as described.58
Protein determination
Protein content was determined with the Thermo Scientific
bicinchoninic acid protein assay reagent with bovine serum albumin
as a standard.
Statistical analysis
The data were analyzed with Student’s t-test when comparing means
between two groups. One-way analysis of variance plus Tukey’s post hoc
multiple comparison test was used when comparing multiple groups.
Two-way analysis of variance plus Bonferroni post-test was used to test
the effects of sham operation or renal IRI on different mouse strains or
treatment groups. The ordinal values of the renal injury scores were
analyzed by the Mann–Whitney nonparametric test. In all cases, a
probability statistic of o0.05 was taken to indicate significance. All
data are expressed throughout the text as means±s.e.m.
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